The U.S. Supreme Court Weighs Mifepristone for Abortion Care
An upcoming Supreme Court ruling could put a stop to telehealth abortion services nationally, and limit access to mifepristone, one of two drugs commonly used in abortion care.
University of California San Francisco
Give to UCSF
Genetic Discovery Reveals Who Can Benefit from Preterm Birth Therapy
In a first, scientists at UCSF and Stanford identified genetic variants that predict whether a patient is likely to respond to treatment for preterm birth. Screening for mutations could allow doctors to target medications to those most likely to benefit. No medication is currently available in the U.S. to treat preterm birth.
Could Two Drugs Be Better Than One for Treating Prostate Cancer?
Combining testosterone-blocking drugs in patients with prostate cancer relapse prevents the spread of cancer better than treatment with a single drug.
Survey Shows Physicians Don’t Understand FDA’s Approval Process
Many physicians are unfamiliar with how the Food and Drug Administration’s (FDA) regulates new drugs and medical devices, and they may be under the impression that the data supporting these approvals
Study Finds Paxlovid Treatment Does Not Reduce Risk of Long COVID
A team of researchers from UC San Francisco has found that Paxlovid did not reduce the risk of developing long COVID for vaccinated, non-hospitalized individuals during their first COVID-19 infection.
Corporate Strategy, National Tragedy
UCSF’s industry archives expose the marketing tactics that fueled the opioid epidemic.
Why You Might Not Find Your Favorite Cold Meds at the Pharmacy
The FDA's recent ruling of phenylephrine as ineffective has led major pharmacies and retailers to pull common cold medicines from their shelves.
Over 30 UCSF Scientists Honored for Highest Impact in Their Fields
Thirty-two UCSF scientists are among the most influential individuals in their respective fields, according to the most recent analysis of research citations by the science and intellectual property company, Clarivate.
Do Combination Therapies Hold Hope for Prostate Cancer Patients?
A phase 1 trial shows promise in treating metastatic prostate cancer with a single priming dose of radioligand therapy and immunotherapy.
Why Progress in Alzheimer’s Disease Treatment Has Taken 30 Years
UCSF's Adam Boxer, MD, PhD, and Harvard neurologist Reisa Sperling, MD, review the history of clinical trials over the past 30 years in Alzheimer’s research with what was learned and how new biomarkers and clinical trial approaches are being used to find more effective treatments in a more efficient way than in the past.
New Care Model Delivers Hepatitis C Treatment to Most Vulnerable
UCSF researchers developed a new neighborhood-based model of care that brings medicine to people immediately after being diagnosed with hepatitis C.
Breakthrough Drug Helps Children with New-Onset Type 1 Diabetes
A study found that children who were recently diagnosed with type 1 diabetes need less supplemental insulin to keep their blood sugar in a healthy range if they use the immunotherapy drug teplizumab.
Neuroscientists to Reveal New Insights into Alzheimer's
UCSF experts to discuss amyloid therapies and dementia research at CTAD conference, addressing equity, novel treatments, and innovative studies.